Do you want to link to this Amgen website and leave Amgen.com.hk?

YOU ARE NOW LEAVING THIS WEBSITE.

Amgen Hong Kong takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Careers Media Amgen Hong Kong
Amgen Worldwide

A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.

PRODUCTS

Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have reached millions of people with our products.

Products

Products available in Hong Kong (Please consult physician for further information on prescription products):

  • kyprolis-trademark
  • lumakras
  • mvasi
  • neulasta
  • neupogen
  • prolia
  • repatha_logo
  • vectibix
  • xgeva

HK-09270-AMGEN-2022-Oct
Date of Approval: Nov 2022

Adverse event or side effect reporting

If you think you may have experienced an adverse event (‘side effect’) after taking or using an Amgen product
please call 800 961 142 , email: medinfo.JAPAC@amgen.com.

Medical enquiries

If you want to contact Amgen for any of the following reasons:

  • you think there may be a defect or quality issue with the Amgen product you have received
  • you have a general medical information enquiry about your Amgen product
    Please call 800 961 142 or email: medinfo.JAPAC@amgen.com.
Products
CTACTA

Our Medicines

At Amgen Hong Kong, we market innovative, high-quality medicines for the treatment of cancer, bone, cardiovascular, rheumatic, inflammatory and hematologic diseases.

products-category-medicine-safetyproducts-category-medicine-safety

Global Patient Safety

Amgen is committed to patient Safety and the Global Patient Safety Department is responsible for oversight of Pharmacovigilance activity. Patient safety is our highest priority. To fulfill our commitment to patient safety, Amgen’s Global Patient Safety Team applies a comprehensive, continuous and rigorous approach to pharmacovigilance.